An evidence-based review of the incidence of CNS bleeding with anti-VEGF therapy in non-small cell lung cancer patients with brain metastases.

No abstract is available for this paper.

• Publication year

  2012

• Venue

  Lung Cancer

• Publication date

  2012-10-01

• Fields of study

  Medicine

• Identifiers
  DOI 10.1016/j.lungcan.2012.07.004PMID 22877947
• External record

  Open on Semantic Scholar

• Source metadata

  Semantic Scholar, PubMed

• No claims are published for this paper.

• No concepts are published for this paper.

• Sunitinib plus erlotinib versus placebo plus erlotinib in patients with previously treated advanced non-small-cell lung cancer: a phase III trial.

  2012cited by this paper
• Safety and efficacy results of the advanced renal cell carcinoma sorafenib expanded access program in North America

  2010cited by this paper
• A front‐line window of opportunity phase 2 study of sorafenib in patients with advanced nonsmall cell lung cancer

  2010cited by this paper
• Safety and efficacy of first-line bevacizumab-based therapy in advanced non-squamous non-small-cell lung cancer (SAiL, MO19390): a phase 4 study.

  2010cited by this paper
• Phase III study of carboplatin and paclitaxel alone or with sorafenib in advanced non-small-cell lung cancer.

  2010cited by this paper
• Bevacizumab Safety in Patients with Central Nervous System Metastases

  2009cited by this paper
• 9006 Safety of bevacizumab (BV) combined with chemotherapy (CTX) in patients (pts) with non-small cell lung cancer (NSCLC): interim results from the ARIES Lung observational cohort study (OCS)

  2009cited by this paper
• 9153 Safety and efficacy of sunitinib in patients with non-small cell lung cancer and irradiated brain metastases

  2009cited by this paper
• A randomized, double-blind, placebo-controlled, phase IIIb trial (ATLAS) comparing bevacizumab (B) therapy with or without erlotinib (E) after completion of chemotherapy with B for first-line treatment of locally advanced, recurrent, or metastatic non-small cell lung cancer (NSCLC).

  2009cited by this paper
• 9171 Low incidence of grade 3 bleeding events and low discontinuation rates associated with first-line bevacizumab (Bev) in patients with advanced NSCLC: data from the SAiL (MO19390) study

  2009cited by this paper
• Phase II, multicenter, uncontrolled trial of single-agent sorafenib in patients with relapsed or refractory, advanced non-small-cell lung cancer.

  2009cited by this paper
• Risk of Intracranial Hemorrhage and Cerebrovascular Accidents in Non-small Cell Lung Cancer Brain Metastasis Patients

  2009influential reference
• Phase III trial of cisplatin plus gemcitabine with either placebo or bevacizumab as first-line therapy for nonsquamous non-small-cell lung cancer: AVAil.

  2009cited by this paper
• Phase II Trial of Temozolomide and Sorafenib in Advanced Melanoma Patients with or without Brain Metastases

  2009cited by this paper
• Safety of bevacizumab in patients with non-small-cell lung cancer and brain metastases.

  2009cited by this paper
• Preliminary treatment patterns and safety outcomes for non-small cell lung cancer (NSCLC) from ARIES, a bevacizumab treatment observational cohort study (OCS)

  2008cited by this paper
• What is the risk of intracranial bleeding during anti-VEGF therapy?

  2008cited by this paper
• Antitumor effects of sunitinib or sorafenib in patients with metastatic renal cell carcinoma who received prior antiangiogenic therapy.

  2008cited by this paper
• High frequency of intracerebral hemorrhage in metastatic renal carcinoma patients with brain metastases treated with tyrosine kinase inhibitors targeting the vascular endothelial growth factor receptor.

  2008cited by this paper
• Intracerebral haemorrhage in primary and metastatic brain tumours

  2008cited by this paper
• Minimally increased risk of cerebrovascular occlusive disease or intracerebral hemorrhage in patients on bevacizumab treatment and association with intracerebral malignancies

  2008cited by this paper
• Acceptable safety of bevacizumab therapy in patients with brain metastases due to non-small cell lung cancer

  2008cited by this paper
• A phase II study of multikinase inhibitor sorafenib in patients with relapsed non-small cell lung cancer (NSCLC)

  2008cited by this paper
• A Phase II Study of Oxaliplatin, Pemetrexed, and Bevacizumab in Previously Treated Advanced Non-small Cell Lung Cancer

  2008cited by this paper
• Multicenter, phase II trial of sunitinib in previously treated, advanced non-small-cell lung cancer.

  2008cited by this paper
• Multidisciplinary management of brain metastases.

  2007cited by this paper
• Approval Summary: Sunitinib for the Treatment of Imatinib Refractory or Intolerant Gastrointestinal Stromal Tumors and Advanced Renal Cell Carcinoma

  2007cited by this paper
• Arterial thromboembolic events in patients with metastatic carcinoma treated with chemotherapy and bevacizumab.

  2007cited by this paper
• Management of single brain metastasis: a practice guideline.

  2007cited by this paper
• Mechanisms of adverse effects of anti-VEGF therapy for cancer

  2007cited by this paper
• Paclitaxel-carboplatin alone or with bevacizumab for non-small-cell lung cancer.

  2006cited by this paper
• Current management of brain metastases, with a focus on systemic options.

  2005cited by this paper
• Brain metastases: epidemiology and pathophysiology

  2005influential reference
• Comparison of MRI and CT for detection of acute intracerebral hemorrhage.

  2004cited by this paper
• Treatment of brain metastases.

  2004cited by this paper
• Brain metastases.

  2003cited by this paper
• Role of vascular endothelial growth factor in physiologic and pathologic angiogenesis: therapeutic implications.

  2002cited by this paper
• Vascular endothelial growth factor 189 mRNA isoform expression specifically correlates with tumor angiogenesis, patient survival, and postoperative relapse in non-small-cell lung cancer.

  2001cited by this paper
• Phase I safety and pharmacokinetic study of recombinant human anti-vascular endothelial growth factor in patients with advanced cancer.

  2001cited by this paper
• Vascular Endothelial Growth Factor Expression in Stage I Non-Small Cell Lung Cancer Correlates With Neoangiogenesis and a Poor Prognosis

  2001cited by this paper
• Expression of vascular endothelial growth factor mRNA in non-small-cell lung carcinomas

  1999cited by this paper
• Intracranial metastases of hepatocellular carcinoma: CT and MRI

  1996cited by this paper
• Brain metastases in adenocarcinoma of the lung: frequency, risk groups, and prognosis.

  1988cited by this paper
• Cerebral neoplasms initially presenting with massive intracerebral hemorrhage.

  1984cited by this paper
• Frequency of brain metastasis in adenocarcinoma and large cell carcinoma of the lung: correlation with survival.

  1983cited by this paper
• Intracranial hemorrhage caused by metastatic tumors

  1977cited by this paper
• Anti‐Angiogenesis: New Concept for Therapy of Solid Tumors

  1972cited by this paper

• Exploring the Spectrum of VEGF Inhibitors’ Toxicities from Systemic to Intra-Vitreal Usage in Medical Practice

  2024cites this paper
• Brain metastases and lung cancer: molecular biology, natural history, prediction of response and efficacy of immunotherapy

  2024cites this paper
• Progress of immune checkpoint inhibitors therapy for non-small cell lung cancer with brain metastases.

  2023cites this paper
• Neurologic Complications of Conventional Chemotherapy and Radiation Therapy

  2023cites this paper
• Tumor microenvironment and exosomes in brain metastasis: Molecular mechanisms and clinical application

  2022cites this paper
• Navigate Towards the Immunotherapy Era: Value of Immune Checkpoint Inhibitors in Non-Small Cell Lung Cancer Patients With Brain Metastases

  2022cites this paper
• Anti-PD-(L)1 immunotherapy for brain metastases in non-small cell lung cancer: Mechanisms, advances, and challenges.

  2021cites this paper
• Peripheral Artery Disease and Stroke

  2020cites this paper
• Neurologic Complications in Patients With Cancer.

  2020cites this paper
• Diagnosis, Treatment, and Prevention of Cancer-Associated Thrombosis

  2020cites this paper
• Candidate genes and pathways associated with brain metastasis from lung cancer compared with lymph node metastasis

  2019cites this paper
• Bevacizumab in Combination with Pemetrexed and Platinum Significantly Improved the Clinical Outcome of Patients with Advanced Adenocarcinoma NSCLC and Brain Metastases

  2019cites this paper
• Operative and peri‐operative considerations in the management of brain metastasis

  2019cites this paper
• Neurological Complications of Targeted Therapies

  2019cites this paper
• Common Vascular Toxicities of Cancer Therapies.

  2019cites this paper
• Bevacizumab in Combination with Pemetrexed and Platinum Signi fi cantly Improved the Clinical Outcome of Patients with Advanced Adenocarcinoma NSCLC and Brain Metastases

  2019cites this paper
• 晚期非小细胞肺癌抗血管生成药物治疗中国专家共识（2019版）

  2019cites this paper
• Neurologic Complications of Systemic Anticancer Therapy.

  2018cites this paper
• Berberine hydrochloride inhibits cell proliferation and promotes apoptosis of non-small cell lung cancer via the suppression of the MMP2 and Bcl-2/Bax signaling pathways.

  2018cites this paper
• Management of the toxicities of common targeted therapeutics for gynecologic cancers.

  2018cites this paper
• Role of bevacizumab in the management of the patient with malignant pleural effusion: more questions than answers

  2018cites this paper
• Paradigm shift of therapeutic management of brain metastases in EGFR-mutant non-small cell lung cancer in the era of targeted therapy

  2017cites this paper
• Bevacizumab in Combination with Platinum-Based Chemotherapy in Patients with Advanced Non-Squamous Non-Small Cell Lung Cancer with or without Brain Metastases: A French Cohort Study (EOLE)

  2017cites this paper
• Clinicopathologic characteristics and survival of patients with gynecologic malignancies metastatic to the brain.

  2016cites this paper
• Vascular Toxicities of Cancer Therapies: The Old and the New – An Evolving Avenue

  2016cites this paper
• Clinical Features of Liver Cancer with Cerebral Hemorrhage

  2016cites this paper
• 脑转移肿瘤细胞及其微环境

  2016cites this paper
• Anti-angiogenetic therapies for central nervous system metastases from non-small cell lung cancer.

  2016cites this paper
• Vascular Toxicities of Cancer Therapies

  2016cites this paper
• Bevacizumab in Patients with Nonsquamous Non–Small Cell Lung Cancer and Asymptomatic, Untreated Brain Metastases (BRAIN): A Nonrandomized, Phase II Study

  2015cites this paper
• Adding bevacizumab to chemotherapy effectively control radioresistant brain metastases in ALK-positive lung adenocarcinoma.

  2015cites this paper
• Inhibition of Angiogenesis in Cancer Management by Antioxidants: Ascorbate and P. leucotomos

  2014cites this paper
• Update on the use of angiogenesis inhibitors in adult patients with brain tumors.

  2014cites this paper
• Bone and brain metastasis in lung cancer: recent advances in therapeutic strategies

  2014cites this paper
• Prognostic factors for brain metastases from non-small cell lung cancer with EGFR mutation: influence of stable extracranial disease and erlotinib therapy

  2014cites this paper
• Systematic Review of the Risk of Adverse Outcomes Associated with Vascular Endothelial Growth Factor Inhibitors for the Treatment of Cancer

  2014cites this paper
• Intramedullary spinal cord hemorrhage after treatment with bevacizumab in a long-term survivor with metastatic non-small-cell lung cancer.

  2014cites this paper
• Serum tumor markers, hypoxia-inducible factor-1α HIF-1α and vascular endothelial growth factor, in patients with non- small cell lung cancer before and after intervention.

  2013cites this paper
• Update on bevacizumab and other angiogenesis inhibitors for brain cancer

  2013cites this paper
• 肺癌脑转移的诊治进展

  2013cites this paper
• Angiogenesis and Lung Cancer

  2013cites this paper
• Chapter 1 Angiogenesis and Lung Cancer

  2013cites this paper